Intended Use

TruSPECT is intended for acceptance, transfer, display, storage, and processing of images for detection of radioisotope tracer uptakes in the patient's body. The device uses various processing modes supported by clinical applications to enhance image quality, depicting, localizing, and quantifying radionuclide tracers and anatomical structures in scanned body tissue for diagnostic purposes.

Technology

TruSPECT includes manual and automatic segmentation, quantitative analysis tools, emission-based attenuation correction using a deep learning model (TruCorr) to estimate attenuation corrected SPECT images directly from non-attenuation corrected ones without anatomical images, and supports CT-based correction. It is Windows OS based, can be configured with multiple software options, and integrates pre-trained neural networks in the iteration reconstruction process.

Performance

The device underwent thorough preclinical validation including risk analysis, design reviews, software development lifecycle adherence, unit and integration testing, performance and safety tests, simulated use testing, and clinical evaluation of the AI-based algorithm using representative clinical exams reviewed by nuclear medicine experts. No new safety concerns were identified and performance was demonstrated as substantially equivalent to predicate devices.

Predicate Devices

No predicate devices specified

Device Timeline

  • 1

    Submission

    7/16/2021

    1 month
  • 2

    FDA Approval

    8/16/2021

Ready to Sharpen Your Edge?

Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.